2025 ELCC | 摘要标题公布！超过100项中国研究入选，你会关注哪些研究？

2025年欧洲肺癌大会（ELCC）将于当地时间3月26日-29日在法国巴黎召开，作为肺癌领域备受关注的重要国际学术会议之一，ELCC汇聚了全球肺癌诊疗的最新技术及研究成果。日前，ELCC官网在线公布了摘要标题（LBA暂未公布），超过100项中国研究入选，快来看看你最关注哪些研究吧！

晚期非小细胞肺癌

摘要号：4O

Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study

Amivantamab联合Lazertinib对比奥希替尼一线治疗EGFR突变晚期非小细胞肺癌（NSCLC）：III期MARIPOSA研究的最终总生存期结果

讲者：杨志新 台湾大学

摘要号：12P

Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small-cell lung cancer (sqNSCLC): 5y update from the phase 3 CameL-sq trial

卡瑞利珠单抗联合化疗作为晚期鳞状NSCLC（sqNSCLC）的一线治疗：III期CameL-sq研究的5年数据更新

讲者：周彩存 上海市东方医院

摘要号：14P

Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: a single-arm, phase 2 trial

一线化学免疫治疗后寡残留NSCLC的巩固立体定向放疗：一项单臂II期试验

讲者：Hongru Chen 上海

摘要号：19P

Subgroup Analysis of First-Line Camrelizumab Plus Chemotherapy in Brain Metastases of NSCLC: Results from the CTONG 2003 Trial

卡瑞利珠单抗联合化疗一线治疗NSCLC脑转移的亚组分析：CTONG 2003研究结果

讲者：Yang-Si Li 广州

摘要号：25P

Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase 3 POSEIDON extended China cohort

度伐利尤单抗联合或不联合tremelimumab联合化疗作为转移性NSCLC的一线治疗：III期POSEIDON研究扩展中国队列的结果

讲者：王洁 中国医学科学院肿瘤医院

摘要号：30P

Clinical Characteristics and Survival Outcomes of Long-Term Responders for advanced Non-Small Cell Lung Cancer Patients with First-line PD-1/PD-L1 Inhibitors: A Multicenter Retrospective Study

晚期NSCLC患者一线使用PD-1/PD-L1抑制剂的长期应答者的临床特征和生存结果：一项多中心回顾性研究

讲者：Zhijuan Du 北京

摘要号：31P

Camrelizumab Plus Chemotherapy as First-Line Treatment for Advanced Non-squamous NSCLC with Brain Metastases: Final overall survival results from the CAP-BRAIN trial

卡瑞利珠单抗联合化疗作为脑转移的晚期非鳞状NSCLC（nsq-NSCLC）一线治疗：CAP-BRAIN研究的最终总生存期结果

讲者：侯雪 中山大学肿瘤防治中心

摘要号：34P

Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC): Phase II study

聚合物胶束紫杉醇（pm-Pac）、卡铂联合信迪利单抗一线治疗晚期nsq-NSCLC的II期研究

讲者：周云 江苏省肿瘤医院

摘要号：35P

Clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis

癌症疫苗在晚期NSCLC患者一线治疗后的临床和安全性结果：系统评价和荟萃分析

讲者：Shaoyi Chen 北京

摘要号：37P

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial

替雷利珠单抗（TIS）联合化疗（CT）一线治疗局部晚期或转移性nsq-NSCLC（LA/M nsq-NSCLC）：随机化、III期RATIONALE-304研究中程序性死亡配体1（PD-L1）表达≥50%亚组分析

讲者：于雁 哈尔滨医科大学附属肿瘤医院

摘要号：39P

Real World Efficacy and Safety of Anlotinib in NSCLC Previously Treated with Immune Checkpoint Inhibitors

安罗替尼在既往接受过免疫检查点抑制剂治疗的NSCLC患者中的实际疗效和安全性

讲者：董宇超 海军军医大学第一附属医院（上海长海医院）

摘要号：46P

Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study

卡瑞利珠单抗、帕博利珠单抗、替雷利珠单抗和信迪利单抗作为NSCLC患者一线治疗的比较：一项回顾性研究

讲者：于韶荣 江苏省肿瘤医院院肿瘤

摘要号：47P

Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy

免疫治疗后进展的NSCLC患者中基于卡度尼利单抗的治疗的疗效和安全性

讲者：于韶荣 江苏省肿瘤医院院肿瘤

摘要号：50P

The impact of prior bevacizumab on the efficacy of anlotinib in advanced non-squamous non-small cell lung cancer

既往使用贝伐珠单抗对安罗替尼在晚期nsq-NSCLC疗效的影响

讲者：王佳蕾 复旦大学附属肿瘤医院肿瘤

摘要号：54P

Efficacy and Safety of Firmonertinib 160mg Combined with Intrathecal Injection Pemetrexed in NSCLC Patients with EGFR Mutations and Leptomeningeal Metastases

160 mg 伏美替尼联合鞘内注射培美曲塞治疗EGFR突变和脑膜转移的NSCLC患者的疗效和安全性

讲者：李晓燕 首都医科大学附属北京天坛医院

摘要号：55P

Clinical value and optimal timing of cranial stereotactic radiotherapy for third-generation EGFR-TKI-treated NSCLC with baseline limited brain metastases

颅内立体定向放疗对接受第三代EGFR-TKI治疗且基线局限性脑转移的NSCLC患者的临床价值和最佳时机

讲者：Silai Yu 上海

摘要号：57P

Safety and Efficacy of Aumolertinib Treatment in Patients with advanced NSCLC Harboring 20ins and uncommon EGFR Mutations (AIM)

阿美替尼治疗EGFR 20ins突变和不常见EGFR突变（AIM）的晚期NSCLC患者的疗效和安全性

讲者：方文峰 中山大学附属肿瘤医院

摘要号：61P

Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PD-L1 expression

奥希替尼联合培美曲塞/卡铂一线治疗PD-L1高表达的EGFR突变晚期NSCLC的反应情况

讲者：Chengdi Weng 广州

摘要号：62P

Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small-cell lung cancer: updated results from FOCUS-A study

伏美替尼联合安罗替尼治疗初治 EGFR突变NSCLC患者：FOCUS-A 研究的最新结果

讲者：韩宝惠 上海交通大学医学院附属胸科医院

摘要号：64P

A real-world study of furmonertinib in uncommon EGFR mutated non-small cell lung cancer with central nervous system metastasis

伏美替尼在罕见的EGFR突变NSCLC伴中枢神经系统转移的真实世界研究

讲者：方申存 南京市胸科医院

摘要号：66P

Long-term Follow-up of Limertinib (ASK120067) in Patients with Locally Advanced or Metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase 2b study

利厄替尼（ASK120067） 在局部晚期或转移性EGFR T790M NSCLC患者中的长期随访：一项多中心、单臂、IIb期研究

讲者：邬麟 中南大学湘雅医学院附属肿瘤医院

摘要号：67P

A Phase II Study of Sunvozertinib Combined with Anlotinib in EGFR-TKIs resistant EGFRm Advanced NSCLC Patients（WU-KONG9）

舒沃替尼联合安罗替尼治疗 EGFR-TKIs耐药EGFR突变晚期NSCLC患者的II期研究（WU-KONG9）

讲者：胡洁 复旦大学附属中山医院

摘要号：68P

Survival Impact of Immunotherapy(IO) after Chemo-failure in EGFR-mutated NSCLC：A post-hoc analysis of the Orient-31 trial

化疗失败后免疫治疗（IO）对EGFR突变NSCLC生存影响：Orient-31研究的事后分析

讲者：李子明 上海市胸科医院

摘要号：69P

PET/Fluorescence Dual-Modal Tracing for Targeted Inhibition of RRM2 to Overcome Osimertinib Resistance in Lung Cancer

PET/荧光双模态追踪靶向抑制RRM2以克服肺癌中的奥希替尼耐药性

讲者：Jinyu Zhu 北京

摘要号：72P

Optimizing Treatment Strategies for EGFR 21L858R mutation Non-Small Cell Lung Cancer with Brain Metastases: A Real-world Analysis of First-Line EGFR-TKI Efficacy

优化EGFR 21L858R突变伴脑转移的NSCLC的治疗策略：一线EGFR-TKI疗效的真实世界分析

讲者：陈丽昆 中山大学肿瘤防治中心

摘要号：73P

Real-World Patterns of Patients with Disease Progression after First-Line Osimertinib for EGFRm aNSCLC in China (FLOURISH Study)

中国EGFRm aNSCLC一线奥希替尼治疗后疾病进展患者的真实世界模式（FLOURISH 研究）

讲者：周建娅 浙江大学医学院附属第一医院

摘要号：75P

Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer

伏美替尼联合安罗替尼用于一线治疗EGFR L858R突变的晚期NSCLC

讲者：周进 四川省肿瘤医院

摘要号：77P

EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as Post Secone-Line Treatment

EGFR突变晚期NSCLC患者在二线治疗后持续受益于阿美替尼

讲者：刘智华 江西省肿瘤医院

摘要号：80P

Final Overall Survival and Long-term Safety Outcomes of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 (METex14) Mutation: An Update from a Phase 3b Study

赛沃替尼治疗MET 14外显子跳跃突变（METex14）局部晚期或转移性NSCLC患者的最终总生存期和长期安全性结果：IIIb期研究的更新

讲者：虞永峰 上海市胸科医院

摘要号：90P

Efficacy of subsequent therapy following the progression of crizotinib in advanced ROS1+ NSCLC in real word setting

在真实世界中克唑替尼作为晚期ROS1阳性NSCLC进展后的后续治疗疗效

讲者：Zihua Zou 北京

摘要号：91P

Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real world setting

克唑替尼在真实世界中治疗晚期ROS1阳性NSCLC的颅内疗效

讲者：Zihua Zou 北京

摘要号：111P

A web-based calculator to Predict the Occurrence of Severe Immune-Related Adverse Events in Non-Small Cell Lung Cancer: Based on a Prospective Study

基于一项前瞻性研究的用于预测NSCLC患者发生严重免疫相关不良事件的网络计算器

讲者：Peng Song 北京

摘要号：121P

Clinical Application and Potential Benefits of En-bloc Biopsy Based on Minimally Invasive Surgery for Advanced Lung Cancer

基于微创手术的整体切除活检在晚期肺癌中的临床应用及潜在益处

讲者：Jianfu Li 广州

摘要号：126TiP

An Open-Label, Single-Arm, Phase Ib Exploratory Study to Evaluate the Safety and Efficacy of Golidocitinib in Combination with Anti-PD-1 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1 Containing Regimens

一项开放标签、单组、Ib期探索性研究，旨在评估戈利昔替尼联合抗PD-1药物在接受抗PD-1方案治疗的局部晚期或转移性NSCLC患者中的疗效和安全性

讲者：钟华 上海交通大学附属胸科医院

摘要号：130TiP

High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients harboring EGFR 21L858R Mutation (AHEAD)

高剂量阿美替尼作为EGFR 21L858R突变的晚期NSCLC患者的一线治疗（AHEAD）

讲者：林立平 广州医科大学附属番禺中心医院

早期非小细胞肺癌

摘要号：50P

Deep learning-based prediction of lung cancer visceral pleural invasion during thoracoscopic surgery: A multicenter study

基于深度学习的胸腔镜手术中肺癌内脏胸膜浸润预测：一项多中心研究

讲者：Hao Xu 北京

摘要号：142P

Identification of the Lymph Node Metastasis Atlas and Optimal Lymph Node Dissection Strategy in Patients with Resectable Lung Invasive Mucinous Adenocarcinoma: A Real-World Multicentre Study

可切除肺浸润性粘液腺癌患者淋巴结转移图谱的识别和最佳淋巴结清扫策略：一项真实世界的多中心研究

讲者：赫捷 中国医学科学院肿瘤医院

摘要号：143P

Microwave Ablation Versus Lobectomy for Ground-Glass Opacity Nodules in the Hilar Region: A Multicenter Prospective Real-World Study on Efficacy and Safety

微波消融与肺叶切除术治疗肺门区域磨玻璃结节：多中心前瞻性真实世界研究的疗效与安全性比较

讲者：Wangrui Liu 上海

摘要号：144P

Perioperative Immunotherapy Treatment in Resectable Non-Small Cell Lung Cancer with KRAS Mutation: A Real-World Study (Peri-R-01)

KRAS突变可切除NSCLC的围手术期免疫治疗：一项真实世界研究（Peri-R-01研究）

讲者：钟华 上海交通大学附属胸科医院

摘要号：145P

Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A NSCLC with High risk factors and EGFR-sensitizing Mutations (APPOINT)

阿美替尼作为辅助治疗在可切除的具有高风险因素和EGFR敏感突变的IA期NSCLC中的疗效和安全性（APPOINT研究）

讲者：韩宝惠 上海交通大学医学院附属胸科医院

摘要号：149P

Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non–small cell lung cancer: A real-world retrospective study

可切除NSCLC新辅助化学免疫疗法与围手术期（化疗）免疫疗法的比较研究：一项真实世界回顾性研究

讲者：Sini N. Li 杭州

摘要号：151P

Real-world Adjuvant Treatment Patterns in Chinese Patients with Resected Stages I to III EGFR-mutated NSCLC: A Multi-center Observational Study (ADDRESS, CATO-2001)

中国I-III期EGFR突变NSCLC患者的真实世界辅助治疗模式：一项多中心观察性研究 （ADDRESS，CATO-2001）

讲者：梁文华 广州医科大学附属第一医院

摘要号：152P

Single-cell analysis revealed the characteristics of tumors with different responses to neoadjuvant chemo-immunotherapy in stage II-IIIB NSCLC

单细胞分析揭示II-IIIB期NSCLC在新辅助化疗免疫治疗中不同反应的肿瘤特征

讲者：卓明磊 北京大学肿瘤医院

摘要号：155P

Survival after wedge resection, segmentectomy and lobectomy for clinical stage IA non-small cell lung cancer: a network meta-analysis and systematic review

临床IA期NSCLC楔形切除术、段切除术和肺叶切除术后的生存情况：网络荟萃分析和系统评价

讲者：沈建飞 浙江省台州医院

摘要号：162P

A Real world study of Adjuvant furmonertinib in patients with stage IA-IIIA EGFR-mutant non-small-cell lung cancer

伏美替尼辅助治疗IA-IIIA EGFR突变NSCLC患者的真实世界研究

讲者：Jiayue Ye 杭州

摘要号：164P

The Clinical Response and Safety of Neoadjuvant Alectinib in Lung Adenocarcinoma with ALK Rearrangement: A Two-Center Retrospective Study

阿来替尼新辅助治疗ALK 重排肺腺癌的临床反应和安全性：一项双中心回顾性研究

讲者：Liang Shi 北京

摘要号：165P

Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-ⅢA Non-Small-Cell Lung Cancer: Updated Results From A multiple-center real-world experience

阿美替尼辅助治疗已切除的EGFR突变IA2-IIIA期NSCLC：来自多中心真实世界经验的最新结果

讲者：Qingyi Zhang 杭州

摘要号：166P

MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study

阿美替尼在EGFR突变阳性IB期和IAII-III期NSCLC完全手术切除后的MRD评估：一项多中心、单臂、开放标签研究

讲者：程超 中山大学附属第一医院

摘要号：176TiP

Perioperative Adebrelimab Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Multicenter, Phase II Trial

围手术期阿得贝利单抗联合化疗治疗可切除的携带EGFR突变NSCLC：一项多中心、II期临床试验

讲者：Gebang Wang 沈阳

摘要号：177TiP

Perioperative Adebrelimab Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Multicenter, Phase II Trial

围手术期阿得贝利单抗联合卡铂、白蛋白结合型紫杉醇和瑞卡西单抗治疗可切除NSCLC的II期临床研究

讲者：Jinghui Wang 北京

摘要号：179TiP

Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)

洛拉替尼作为IB-IIIB期ALK重排NSCLC的新辅助治疗（NEOLORA）

讲者：杨帆 北京大学人民医院

影像学检查和分期

摘要号：185P

Validation of the ninth edition of N descriptor in patients with resected non-small cell lung cancer receiving neoadjuvant therapy

第九版N描述符在接受新辅助治疗的切除NSCLC患者中的验证

讲者：Haojie Si 上海

局部晚期非小细胞肺癌

摘要号：197P

Efficacy and Safety of Induction Chemo-Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Multicenter Retrospective Study

不可切除的III期NSCLC诱导化疗-免疫治疗的疗效和安全性：一项真实世界的多中心回顾性研究

讲者：Wenlu Chen 太原

摘要号：202P

Durvalumab after Definitive Chemoradiation (dCRT) in Non-small cell lung cancer (NSCLC) patients with Actionable Driver Mutations

驱动基因突变阳性NSCLC患者在接受根治性放化疗（dCRT）后使用度伐利尤单抗

讲者：Jason C S 香港九龙

摘要号：205P

EGFR-TKI Combined with Chemotherapy versus EGFR-TKI Alone for locally advanced EGFR-mutant NSCLC: A Real-World Study

EGFR-TKI联合化疗与单独EGFR-TKI治疗局部晚期EGFR突变型NSCLC：一项真实世界研究

讲者：Yu Jiang 广州

摘要号：209P

Four-Year Outcomes with Perioperative Toripalimab plus Chemotherapy in Resectable Stage III Non-Small Cell Lung Cancer (NeoTAP01 Study)

围手术期特瑞普利单抗联合化疗治疗可切除的III期NSCLC的4年结果（NeoTAP01研究）

讲者：Yuheng Zhou 广州

摘要号：212P

Recurrence in Patients with Non–Small Cell Lung Cancer Achieving Pathological Complete Response after Neoadjuvant Treatment

新辅助治疗后达到病理完全缓解的NSCLC患者的复发情况

讲者：Yuechun Lin 广州

摘要号：214P

Refining Central Lung Cancer Surgery: Uniportal Video-Assisted Thoracic Surgery with Three-Dimensional Vascular Mapping After Neoadjuvant Chemoimmunotherapy

改进中心型肺癌手术：新辅助化学免疫治疗后的单孔胸腔镜手术结合三维血管成像

讲者：罗志林 重庆医科大学附属第三医院

摘要号：215P

Safety and Necessity of Mediastinal Lymph Nodes Dissection Omission Following Nodal Clearance with Neoadjuvant Immunochemotherapy in cN0/N1 Non-Small Cell Lung Cancer

cN0/N1 NSCLC新辅助免疫化疗淋巴结清除后淋巴结清扫术切除纵隔淋巴结清扫的安全性和必要性

讲者：Yuheng Zhou 广州

摘要号：216P

Prognostic Impacts of Skip Metastasis in N2a and N2b Subgroups in Non-Small Cell Lung Cancer：Insights from a Large Cohort

NSCLC的N2a和N2b亚组中跳跃性转移的预后影响：来自大规模队列的见解

讲者：Shenhua Liang 广州

摘要号：228P

Type VII Collagen Enhances Matrix Viscoelasticity and Modulates Immune Response in Advanced Lung Adenocarcinoma

VII型胶原蛋白增强基质粘弹性并调节晚期肺腺癌中的免疫反应

讲者：Pengxu Kong 杭州

摘要号：229P

A Randomized, Controlled, Open-label Phase Ⅱ study of Becotatug (JMT101) Combined with Docetaxel (Albumin-Bound, HB1801) for Treatment of Patients (pts) with Locally Advanced/Recurrent or Distant Metastatic Squamous Cell Non-Small Cell Lung Cancer (sqNSCLC) (BATTLE study)

一项随机、对照、开放标签的II期研究（BATTLE研究）：Becotatug（JMT101）联合多西他赛（白蛋白结合型，HB1801）治疗局部晚期/复发或远处转移性sqNSCLC

讲者：张力 中山大学肿瘤防治中心

摘要号：237P

125I particles implantation is an effective therapy for oligo-progression during immunotherapy

125I粒子植入是免疫治疗中治疗少数进展的有效疗法

讲者：Xiao Fu 西安

肺转移

摘要号：252P

Surgical and Pathology Outcome of a Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients: Feasibility Evaluation

EGFR TKI联合原发肿瘤切除治疗EGFR突变转移性NSCLC患者的随机II期试验的手术和病理结果：可行性评估

讲者：陈沛兴 台湾大学医学院附设医院新竹台大分院

摘要号：254P

Serial monitoring of cerebrospinal fluid in lung cancer patients with brain metastases via the ommaya reservoir as a predictive indicator of therapeutic efficacy and clinical prognosi

通过瘤库对肺癌脑转移患者脑脊液的连续监测作为治疗效果和临床预后的预测指标

讲者：方申存 南京市胸科医院

摘要号：258P

Pan-cancer analyses reveal tissue-type-specific intracellular bacteria in lung metastatic cancer

泛癌分析揭示肺转移癌组织类型特异性细胞内细菌

讲者：Haiming Chen 福州

摘要号：259P

Association of Gut Microbiome with Radiotherapy Efficacy in Lung Cancer Patients with Brain Metastases

肺癌脑转移患者肠道微生物组与放疗疗效的关系

讲者：夏铀铀 连云港市第一人民医院

预防，早期发现，流行病学，烟草控制

摘要号：264P

Innovative Portable Breathomic Device For Early Non-Invasive Differentiation Of Benign And Malignant Lung Nodules

创新便携式呼吸装置用于肺结节良恶性早期无创鉴别

讲者：梁恒瑞 广州医科大学附属第一医院

摘要号：265P

Association Between Digestive System Diseases and Lung Cancer Risk: A Comprehensive Evaluation based on UK Biobank

消化系统疾病与肺癌风险的关系：基于英国生物银行的综合评估

讲者：Yi Feng 广州

摘要号：266P

Association Between Serum Branched-Chain Amino Acids and Cancer Risk: Findings from a Prospective Cohort Study in the UK Biobank

血清支链氨基酸与癌症风险之间的关系：来自英国生物银行前瞻性队列研究的结果

讲者：Yi Feng 广州

摘要号：276P

A multicenter exhaled breath metabolomics lung cancer screening model based on PTR-TOF MS

基于PTR-TOF MS的多中心呼气代谢组学肺癌筛查模型

讲者：Chen Huang 成都

摘要号：277P

Preliminary results of LC-SHIELD study (Lung Cancer Screening in HIgh risk non-smokErs with artificial inteLligence Device)

LC-SHIELD研究（使用人工智能设备筛查高危非吸烟者肺癌）的初步结果

讲者：Siu Ching M. Li 香港沙田

摘要号：278P

Dynamic Machine Learning for Early Lung Cancer Identification Using Longitudinal Clinical and Laboratory Data

利用纵向临床和实验室数据进行早期肺癌识别的动态机器学习

讲者：叶文君 广州医科大学附属第一医院

摘要号：279P

Study on screening and diagnosis model of smokers based on PTR-TOF-MS

基于PTR-TOF-MS的吸烟者筛查诊断模型研究

讲者：Chen Huang 成都

小细胞肺癌

摘要号：300P

CT-based intratumoral and peritumoral radiometric characteristics accurately predict the risk of distant metastasis in small cell lung cancer

基于CT的肿瘤内和肿瘤周围放射学特征可以准确预测小细胞肺癌（SCLC）远处转移的风险

讲者：王苒 安徽医科大学第一附属医院

摘要号：302P

Phase 2 study of the efficacy and safety of BNT327/PM8002 plus systemic chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC)

BNT327/PM8002联合全身化疗作为一线治疗广泛期小细胞肺癌（ES-SCLC）的有效性和安全性的II期研究

讲者：程颖 吉林省肿瘤医院

摘要号：304P

Prognostic markers and Molecular Insights: Navigating SCLC with Liver Metastasis

预后标志物和分子洞察：导览伴有肝转移的SCLC

讲者：Jing Ding 成都

摘要号：308P

Real-world outcomes in extensive-stage small cell lung cancer treated with first-line serplulimab: The nationwide observational ASTRUM-005R study

一线斯鲁利单抗治疗大分期SCLC的实际结果：全国观察性ASTRUM-005R研究

讲者：Lin Wu 长沙

摘要号：310P

Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

ES-SCLC患者在一线铂基化疗（Chemo）加PD-1/PD-L1抗体后，索凡替尼加PD-1/PD-L1抗体的最终总生存期

讲者：胡毅 中国人民解放军总医院

摘要号：317P

Impact of Induction Chemotherapy Cycles on the Efficacy of First-Line Atezolizumab Combined with Chemotherapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

诱导化疗周期对一线阿替利珠单抗联合化疗治疗ES-SCLC疗效的影响

讲者：Mengxing You 北京

摘要号：318P

Impact of Prophylactic Cranial Irradiation on Survival in Extensive-Stage Small Cell Lung Cancer Receiving First-Line Chemoimmunotherapy: A Propensity Score-Matched Study

预防性颅照射对接受一线化学免疫治疗的大分期SCLC患者生存的影响：一项倾向评分匹配研究

讲者：范云 浙江省肿瘤医院

摘要号：320P

Lysine-specific Demethylase 1A (LSD1) inhibition attenuates phenotypic transition and delays the tumor relapse to radioimmunotherapy in small cell lung cancer

赖氨酸特异性去甲基酶1A （LSD1）抑制可减轻SCLC的表型转变并延缓肿瘤对放射免疫治疗的复发

讲者：Hui Wang 成都

摘要号：322P

Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

细胞外小泡mirna作为ES-SCLC免疫化疗疗效的预测性生物标志物

讲者：Wei Zhang 上海

摘要号：328P

The Prognostic Analysis and Model Establishment of Central and Peripheral Small Cell Lung Cancer

中枢性和外周性SCLC的预后分析及模型建立

讲者：Xiao Fu 西安

摘要号：329P

Intracranial efficacy of YL201, a novel B7-H3-targeting antibody-drug conjugate (ADC), in patients (pts) with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)

新型b7-h3靶向抗体偶联药物（ADC）YL201在SCLC和NSCLC患者中的颅内疗效

讲者：赵洪云 中山大学肿瘤防治中心

摘要号：331P

A single-arm, open-label, prospective, single-center clinical study on the treatment of patinum-resistant relapse small cell lung cancer with nab-paclitaxel combined with apatinib

单臂、开放标签、前瞻性、单中心临床研究nab-紫杉醇联合阿帕替尼治疗铂耐药复发SCLC

讲者：杨雪 北京大学肿瘤医院

摘要号：332P

Updated phase II efficacy and safety results of BNT327/PM8002 combined with paclitaxel as second-line (2L) therapy in small cell lung cancer (SCLC)

BNT327/PM8002联合紫杉醇作为二线治疗SCLC的最新II期疗效和安全性结果

讲者：程颖 吉林省肿瘤医院

摘要号：333P

Safety and effectiveness of adebrelimab as second- or later-line treatment in extensive-stage small-cell lung cancer: a prospective, real-world study

阿得贝利单抗作为二线或后线治疗ES-SCLC的安全性和有效性：一项前瞻性的现实世界研究

讲者：Xiaoli Liu 青岛

摘要号：336P

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

度伐利尤单抗作为局限期小细胞肺癌（LS-SCLC）的巩固治疗：ADRIATIC研究中国亚组分析

讲者：程颖 吉林省肿瘤医院

摘要号：337P

Safety and Effectiveness of hyper-fractionated Simultaneous Integrated Boost in Definitive Chemoradiation for Limited-Stage Small Cell Lung Cancer

超分割同步整合放疗在LS-SCLC放化疗中的安全性和有效性

讲者：Wenqiang Guan 自贡

摘要号：338P

Preoperative immunochemotherapy versus chemotherapy for patients with stage I–IIIB small-cell lung cancer

I-IIIB期SCLC患者术前免疫化疗与化疗

讲者：Jiacong Liu 杭州

摘要号：339P

A Retrospective Real-World Study of Neoadjuvant Chemotherapy in Patients with Resectable Small-Cell Lung Cancer

可切除SCLC患者新辅助化疗的回顾性现实世界研究

讲者：Wengang Zhang 上海

摘要号：343TiP

Maintenance Therapy with Fuzuloparib plus Adebrelimab for ES-SCLC after First-Line Induction with Fuzuloparib plus Adebrelimab and Chemotherapy: A Prospective, Single-Arm, Phase II Clinical Study

Fuzuloparib联合阿得贝利单抗一线诱导和化疗后ES-SCLC的维持治疗：一项前瞻性单组II期临床研究

讲者：Huiru Xu 太原

摘要号：344TiP

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): a multi-center, single-arm, phase 2 clinical trial

阿得贝利单抗联合阿帕替尼用于一线阿得贝利单抗联合化疗诱导后ES-SCLC的维持治疗（CLOG2402-ADAPT）：一项多中心、单组、II期临床试验

讲者：张凌云 中国医科大学附属第一医院

转化研究

摘要号：348P

Pulsed High-Dose Fractionated Radiotherapy Combined with Enhanced Immunotherapy in the Treatment of Driver Gene-Negative Advanced Non-small-cell Lung Cancer: A Clinical Study

脉冲高剂量分割放疗联合强化免疫治疗驱动基因阴性晚期NSCLC的临床研究

讲者：Chuanwang Miao 济南

摘要号：351P

The Application of Peripheral Blood Immune Profiling in Personalized Treatment of Advanced Lung Cancer: A Nomogram Approach

外周血免疫谱分析在晚期肺癌个体化治疗中的应用：一种Nomogram方法

讲者：Chuanwang Miao 济南

摘要号：356P

DDR2 inhibition reveals a T cell immune checkpoint that controls lung cancer immunosurveillance

DDR2抑制揭示控制肺癌免疫监测的T细胞免疫检查点

讲者：Shuai Zhang 武汉

摘要号：357P

Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02

TROP2定量连续评分（QCS）归一化膜比（NMR）与中国晚期/转移性NSCLC（a/mNSCLC）患者在TROPION-PanTumor02研究中接受datopotamab deruxtecan （Dato-DXd）治疗的相关性

讲者：吴一龙 广东省人民医院

摘要号：359P

Prognostic role of B7H3 in non-small cell lung cancer patients treated with immune checkpoint inhibitors

B7H3在免疫检查点抑制剂治疗的NSCLC患者中的预后作用

讲者：Xinxin Zhi 上海

摘要号：370P

Transcriptome Data-Based Prognosis Prediction Model for Lung Adenocarcinoma Using an Image Deep Learning Approach

基于转录组数据的肺腺癌图像深度学习预后预测模型

讲者：Hsuanyu Chen 台北

摘要号：372P

Sympathetic Signals Promote Immunosuppressive Neutrophils for Tumor Progression in the Lung

交感信号促进免疫抑制性中性粒细胞在肺肿瘤进展中的作用

讲者：Ruoyi Jin 北京

摘要号：375P

Multi-Omics Revealed Unique Metabolic Resistance Mechanisms to Third-Generation EGFR-TKI in EGFR-Mutant Non-Small Cell Lung Cancer

多组学揭示EGFR突变NSCLC对第三代EGFR-TKI的独特代谢耐药机制

讲者：Ruyun Gao 北京

摘要号：378P

LncRNA RP11-888D10.4 expression upregulates invasion and metastasis through epithelial-mesenchymal transition in lung cancer cells

LncRNA RP11-888D10.4表达上调肺癌细胞上皮-间质转化的侵袭转移

讲者：Jung-Jyh Hung 台北

摘要号：381P

Empowering Global Oncology: DBS-TARGET Enables High-Sensitivity Mutation Detection Anywhere

授权全球肿瘤学：DBS-TARGET使高灵敏度突变检测无处不在

讲者：Liu Jingjing 合肥

摘要号：382P

Unveiling DEFB1 as a Novel Driver and Promising Therapeutic Target in Lung Adenocarcinoma

揭示DEFB1作为肺腺癌的新驱动因子和有希望的治疗靶点

讲者：Cheng Zhan 上海

摘要号：386P

Comparison between CSF circulating tumor DNA, cytology and imaging for diagnosis of leptomeningeal metastases in non-small cell lung cancer: a retrospective study

NSCLC脑膜转移诊断中脑脊液循环肿瘤DNA、细胞学和影像学的比较：一项回顾性研究

讲者：Joyce M. Leung 香港沙田

摘要号：392P

Integrating Wearable Devices and Electronic Patient Reported Outcomes for Continuous Perioperative Monitoring: Novel Evidence for Enhanced Recovery after Thoracic Surgery

整合可穿戴设备和电子患者报告结果连续围手术期监测：提高胸外科术后恢复的新证据

讲者：Runchen Wang 广州

摘要号：399P

Microplastic Exposure in COPD Alters the Immune Microenvironment: Implications for Tumor-Promoting Inflammation

慢性阻塞性肺病的微塑料暴露改变了免疫微环境：对促肿瘤炎症的影响

讲者：Wangrui Liu 上海

肿瘤生物学和病理学

摘要号：404P

The 41BB agonist potentiates the therapeutic efficacy of irreversible electroporation combined with immune adjuvants for lung cancer by promoting not only tissue-resident memory CD8 + T cell but also cDC1 responses

41BB激动剂通过促进组织驻留记忆CD8 + T细胞和cDC1反应，增强不可逆电穿孔联合免疫佐剂治疗肺癌的疗效

讲者：Yu Feng 苏州

摘要号：406P

Rescuing treatment-induced epigenetic alterations in cancer-associated fibroblasts as a potential chemo-sensitization strategy in stroma-rick tumors

在间质瘤中挽救治疗诱导的癌症相关成纤维细胞的表观遗传改变作为一种潜在的化学增敏策略

讲者：Kelvin K. Tsai 台北

摘要号：413P

Classifying Multiple Lung Cancers by Spatial Microenvironment: Tertiary Lymphoid Structures at Interface Zone as Immune Hubs and Prognostic Determinants

空间微环境对多发性肺癌的分类：界面区三级淋巴结构作为免疫枢纽和预后决定因素

讲者：Xiaoqiu Yuan 北京

摘要号：414P

Exosome Whisperers: Decoding SPHK1's Role in Cisplatin-induced immune escape of NSCLC

外泌体Whisperers：解码SPHK1在顺铂诱导的NSCLC免疫逃逸中的作用

讲者：Huan Gao 西安

其他

摘要号：426P

Ototoxicity and Safety Profile of Capmatinib in NSCLC: Insights from Real-World FAERS Data (2020-2023)

卡马替尼治疗NSCLC的耳毒性和安全性：来自真实世界FAERS数据的见解（2020-2023）

讲者：Siqi Xu 福州

备注：排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

编辑：Squid

排版：Squid

执行：Aurora

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。